Biphenyl carboxylic amide p38 kinase inhibitors
Compound of formula (I): or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
1. A compound of formula (I):
wherein
R 1 is selected from hydrogen, C 1-6 alkyl optionally substituted by up to three groups independently selected from C 1-6 alkoxy, halogen and hydroxy, C 2-6 alkenyl, C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, phenyl optionally substituted by up to three groups independently selected from R 5 and R 6 or heteroaryl optionally substituted by up to three groups independently selected from R 5 and R 6 ,
R 2 is selected from hydrogen, C 1-6 alkyl or —(CH 2 ) p —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups,
or (CH 2 ) m R 1 and R 2 , together with the nitrogen atom to which they are bound, form a four- to six-membered heterocyclic ring optionally substituted by up to three C 1-6 alkyl groups;
R 3 is chloro or methyl;
R 4 is the group —NH—CO—R 7 or —CO—NH—(CH 2 ) p —R 8 ;
R 5 is selected from C 1-6 alkyl, C 1-6 alkoxy, —(CH 2 ) p —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, —CONR 9 R 10 , —NHCOR 10 , —SO 2 NHR 9 , —CH 2 ) q NHSO 2 R 10 , halogen, CN, OH, —(CH 2 ) q NR 11 R 12 or trifluoromethyl;
R 6 is selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, trifluoromethyl or —(CH 2 ) q NR 11 R 12 ;
R 7 is selected from hydrogen, C 1-6 alkyl, —(CH 2 ) p —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, trifluoromethyl, —(CH 2 ) r heteroaryl optionally substituted by R 13 and/or R 14 or —(CH 2 ) r phenyl optionally substituted by R 13 and/or R 14 ;
R 8 is selected from hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, CONHR 9 , phenyl optionally substituted by R 13 and/or R 14 or heteroaryl optionally substituted by R 13 and/or R 14 ;
R 9 and R 10 are each independently selected from hydrogen or C 1-6 alkyl, or
R 9 and R 10 , together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R 15 , wherein the ring is optionally substituted by up to two C 1-6 alkyl groups;
R 11 is selected from hydrogen, C 1-6 alkyl or —(CH 2 ) p —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups;
R 12 is selected from hydrogen or C 1-6 alkyl, or
R 11 and R 12 , together with the nitrogen atom to which they are bound, form a five or six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R 15 ;
R 13 is selected from C 1-6 alkyl, C 1-6 alkoxy, —CH 2 ) p —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, —CONR 9 R 10 , —NHCOR 10 , halogen, CN, —(CH 2 ) q NR 11 R 12 , trifluoromethyl, phenyl optionally substituted by one or more R 14 groups or heteroaryl optionally substituted by one or more R 14 groups;
R 14 is selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, trifluoromethyl or —NR 11 R 12 ;
R 15 is selected from hydrogen or methyl;
X and Y are each independently selected from hydrogen, methyl or halogen;
Z is selected from —(CH 2 ) s OR 16 , —(CH 2 ) s NR 16 R 17 , —(CH 2 ) s CH 2 CH 2 R 16 , —(CH 2 ) s COOR 16 , —(CH 2 ) s CONR 16 R 17 , —(CH 2 ) s NHCONR 16 R 17 , —(CH 2 ) s SO 2 R 16 , —(CH 2 ) s SO 2 NR 16 R 17 or —(CH 2 ) s NHSO 2 R 16 ;
R 16 is selected from hydrogen, C 1-6 alkyl optionally substituted by up to two hydroxy groups, —(CH 2 ) t OR 18 , —(CH 2 ) t NR 18 R 19 , —(CH 2 ) t NHSO 2 R 18 , —(CH 2 ) t CONR 18 R 19 , —(CH 2 ) t COOR 18 , —(CH 2 ) t heteroaryl optionally substituted by up to two groups independently selected from halogen, C 1-6 alkyl or oxo, or —(CH 2 ) t phenyl optionally substituted by up to two groups independently selected from halogen, C 1-6 alkyl or C 1-6 alkoxy,
R 17 is selected from hydrogen or C 1-6 alkyl, or
R 16 and R 17 , together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R 15 , wherein the ring is optionally substituted by up to two groups independently selected from oxo, halogen or C 1-6 alkyl;
R 18 and R 19 are each independently selected from hydrogen or C 1-6 alkyl optionally substituted by up to two hydroxy groups, or
R 18 and R 19 , together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R 15 , wherein the ring is optionally substituted by up to two groups independently selected from oxo, halogen or C 1-6 alkyl;
m is selected from 0, 1, 2, 3 or 4, wherein each carbon atom of the resulting carbon chain may be optionally substituted with up to two groups independently selected from C 1-6 alkyl or halogen;
n is 1;
p is selected from 0, 1 or 2;
q is selected from 0, 1, 2 or 3;
r is selected from 0 or 1;
s is selected from 0, 1, 2, 3 and 4; and
t is selected from 1,2, 3or 4;
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 wherein R 1 is selected from C 1-6 alkyl, C 3-7 cycloalkyl or phenyl optionally substituted by up to three groups selected from R 5 and R 6 .
3. A compound according to claim 1 wherein R 1 is C 3-6 cycloalkyl.
4. A compound according to claim 1 wherein R 2 is hydrogen.
5. A compound according to claim 1 wherein m is 0 or 1.
6. A compound according to claim 1 wherein m is 1.
7. A compound according to claim 1 wherein R 8 is C 3-6 cycloalkyl.
8. A compound according to claim 1 wherein Z is selected from —(CH 2 ) s OR 16 , —(CH 2 ) s NR 16 R 17 , —(CH 2 ) s NHCONR 16 R 17 and —(CH 2 ) s NHSO 2 R 16 .
9. A compound according to claim 1
N 3 -cyclopropyl-5-fluoro-2′-hydroxy-6-methyl-N 4 ′-[(4-methylphenyl)methyl]-3,4′- biphenyldicarboxamide;
N 3 -cyclopropyl-N 4 ′-(2,2dimethylpropyl)5-fluoro-6-methyl-2′-{[(methyloxy)methyl]oxy}-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-5-fluoro-6-methyl-2′-{[(methyloxy)methyl]oxy}-N 4 ′-(2-methylpropyl)-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-N 4 ′-(cyclopropylmethyl)-5-fluoro-6-methyl-2′-{[(methyloxy)methyl]oxy}-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-5-fluoro-6-methyl-2′-{[(methyloxy)methyl]oxy}-N 4 ′-{[4-(methyloxy)phenyl]methyl}-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-5-fluoro-6-methyl-2′-{[(methyloxy)methyl]oxy}-N 4 ′-[(1R)-1,2,2-trimethylpropyl]-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-N 4 ′-[(1R)-1,2-dimethylpropyl]-5-fluoro-6-methyl-2′-{[(methyloxy)methyl]oxy}-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-N 4 ′-(2,2-dimethylpropyl)-5-fluoro-2′-hydroxy-6-methyl-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-5-fluoro-2′-hydroxy-6-methyl-N 4 ′-(2-methylpropyl)-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-N 4 ′-(cyclopropylmethyl)-5-fluoro-2′-hydroxy-6-methyl-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-5-fluoro-2′-hydroxy-6-methyl-N 4 ′-{[4-(methyloxy)phenyl]methyl}-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-5-fluoro-2′-hydroxy-6-methyl-N 4 ′-[(1R)-1,2,2-trimethylpropyl]-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-N 4 ′-[(1R)-1,2-dimethylpropyl]-5-fluoro-2′-hydroxy-6-methyl-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-N 4 ′-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2′-(methyloxy)-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-5-fluoro-6-methyl-2′-(methyloxy)-N 4 ′-(2-methylpropyl)-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-N 4 ′-(cyclopropylmethyl)-5-fluoro-6-methyl-2′-(methyloxy)3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-5-fluoro-6-methyl-2′-(methyloxy)-N 4 ′-{[4-(methyloxy)phenyl]methyl}-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-5-fluoro-6-methyl-2′-(methyloxy)-N 4 ′-[(1R)-1,2,2-trimethylpropyl]-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-N 4 ′-[(1R)-1,2-dimethylpropyl]-5-fluoro-6-methyl-2′-(methyloxy)-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-N 4 ′-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2′-(propyloxy)-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-2′-{[3-(dimethylamino)propyl]oxy}-N 4 ′-(2,2-dimethylpropyl)5-fluoro-6-methyl-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-N 4 ′-(2,2dimethylpropyl)-5-fluoro-6-methyl-2′-({2-[(methylsulfonyl)amino]ethyl}oxy)-3,4′-biphenyldicarboxamide;
4-[(5′-[(cyclopropylamino)carbonyl]-4-{[(2,2-dimethylpropyl)amino]carbonyl}-3′-fluoro-2′-methyl-2-biphenylyl)oxy]butanoic acid;
2′-[(4-amino-4-oxobutyl)oxy]-N 3 -cyclopropyl-N 4 ′-(2,2-dimethylpropyl)-5-fluoro-6-methyl-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-N 4 ′-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2′-{[4-(methylamino)-4-oxobutyl]oxy}-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-N 4 ′-(2,2-dimethylpropyl)-5-fluoro-2′-[(4-hydroxybutyl)oxy]-6-methyl-3,4′-biphenyldicarboxamide;
N 3 -cyclopropyl-N 4 ′-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2′-{[3-(1,3,4-oxadiazol-2-yl)propyl]oxy}-3,4′-biphenyldicarboxamide; and
N 3 -cyclopropyl-N 4 ′-(2,2-dimethylpropyl)-5-fluoro-2′-(hydroxymethyl)-6-methyl-3,4′-biphenyldicarboxamide;
or a pharmaceutically acceptable salt thereof.
10. A process for preparing a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, which comprises:
(a) reacting a compound of (II)
in which R 1 , R 2 , Z, m and n are as defined in claim 1 and W is halogen, with a compound of formula (III)
in which R 3 , R 4 , X and Y are as defined in claim 1 , in the presence of a catalyst, or
(b) reacting a compound of formula (VIII)
with a compound of formula (III) as hereinbefore defined and then reacting the acid thus formed with an amine of formula (V)
in which R 1 , R 2 and m are as defined in claim 1 , under amide forming conditions
(c) reacting a compound of formula (II) as hereinbefore defined with a compound of formula (IX)
in which R 3 , R 4 , X and Y are as defined in claim 1 , in the presence of a catalyst,
(d) reacting a compound of formula (X)
in which R 3 , R 4 , X, Y, Z and n are as defined in claim 1 , with an amine compound of formula (V) as defined above, under amide forming conditions,
(e) final stage modification of one compound of formula (I) into another compound of formula (I), or
(f) conversion of a compound of formula (XII)
in which Z′ is a group convertible to Z as defined in claim 1 .
11. A pharmaceutical composition comprising at least one compound according to claim 1 , or a pharmaceutically acceptable salt thereof, in association with one or more pharmaceutically acceptable excipients, diluents and/or carriers.
12. A method for treating inflammation in a human in need thereof comprising administering to said human an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
13. A compound of formula (IA):
wherein
R 1 is selected from hydrogen, C 1-6 alkyl optionally substituted by up to three groups independently selected from C 1-6 alkoxy, halogen or hydroxy, C 2-6 alkenyl, C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, phenyl optionally substituted by up to three groups independently selected from R 5 and R 6 , or heteroaryl optionally substituted by up to three groups independently selected from R 5 and R 6 ,
R 2 is selected from hydrogen, C 1-6 alkyl or —(CH 2 ) p —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups,
or (CH 2 ) m R 1 and R 2 , together with the nitrogen atom to which they are bound, form a four- to six-membered heterocyclic ring optionally substituted by up to three C 1-6 alkyl groups;
R 3 is chloro or methyl;
R 4 is the group —NH—CO—R 7 or —CO—NH—(CH 2 ) p —R 8 ;
R 5 is selected from C 1-6 alkyl, C 1-6 alkoxy, —(CH 2 ) p —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, —CONR 9 R 10 , —NHCOR 10 , —SO 2 NHR 9 , —(CH 2 ) q NHSO 2 R 10 , halogen, CN, OH, —(CH 2 ) q NR 11 R 12 or trifluoromethyl;
R 6 is selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, trifluoromethyl or —(CH 2 ) q NR 11 R 12 ;
R 7 is selected from hydrogen, C 1-6 alkyl, —(CH 2 ) p —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, trifluoromethyl, —(CH 2 ) r heteroaryl optionally substituted by R 13 and/or R 14 or —(CH 2 ) r phenyl optionally substituted by R 13 and/or R 14 ;
R 8 is selected from hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, CONHR 9 , phenyl optionally substituted by R 13 and/or R 14 or heteroaryl optionally substituted by R 13 and/or R 14 ;
R 9 and R 10 are each independently selected from hydrogen or C 1-6 alkyl, or
R 9 and R 10 , together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R 15 , wherein the ring is optionally substituted by up to two C 1-6 alkyl groups;
R 11 is selected from hydrogen, C 1-6 alkyl or —(CH 2 ) p —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups,
R 12 is selected from hydrogen or C 1-6 alkyl, or
R 11 and R 12 , together with the nitrogen atom to which they are bound, form a five or six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R 15 ;
R 13 is selected from C 1-6 alkyl, C 1-6 alkoxy, —(CH 2 ) p —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, —CONR 9 R 10 , —NHCOR 10 , halogen, CN, —(CH 2 ) q NR 11 R 12 , trifluoromethyl, phenyl optionally substituted by one or more groups or heteroaryl optionally substituted by one or more groups;
R 14 is selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, trifluoromethyl or —NR 11 R 12 ;
R 15 is selected from hydrogen or methyl;
X and Y are each independently selected from hydrogen, methyl or halogen;
Z is selected from —(CH 2 ) s OR 16 , —(CH 2 ) s NR 16 R 17 , —(CH 2 ) s CH 2 CH 2 R 16 , —(CH 2 ) s COOR 16 , —(CH 2 ) s CONR 16 R 17 , —(CH 2 ) s NHCOR 16 , —(CH 2 ) s NHCONR 16 R 17 , —(CH 2 ) s SO 2 R 16, —(CH 2 ) s SO 2 NR 16 R 17 or —(CH 2 ) s NHSO 2 R 16 ;
R 16 is selected from hydrogen, C 1-6 alkyl, —(CH 2 ) t OR 18 , —(CH 2 ) t NR 18 R 19 , —(CH 2 ) t COOR 18 , —(CH 2 ) t heteroaryl optionally substituted by up to two groups independently selected from halogen or C 1-6 alkyl, or is a —(CH 2 ) t phenyl optionally substituted by up to two groups independently selected from halogen, C 1-6 alkyl or C 1-6 alkoxy,
R 17 is selected from hydrogen or C 1-6 alkyl, or
R 16 and R 17 , together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R 15 , wherein the ring is optionally substituted by up to two groups independently selected from oxo, halogen and C 1-6 alkyl;
R 18 and R 19 are each independently selected from hydrogen or C 1-6 alkyl, or
R 18 and R 19 , together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R 15 , wherein the ring is optionally substituted by up to two groups independently selected from oxo, halogen or C 1-6 alkyl;
m is selected from 0, 1, 2, 3 or 4, wherein each carbon atom of the resulting carbon chain may be optionally substituted with up to two groups independently selected from C 1-6 alkyl or halogen;
n is 1;
p is selected from 0, 1 or 2;
q is selected from 0, 1, 2 or 3;
r is selected from 0 or 1;
s is selected from 0, 1, 2, 3 or 4; and
t is selected from 2, 3 or 4;
or a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition comprising a compound according to claim 13 , or a pharmaceutically salt thereof, in association with one or more pharmaceutically acceptable excipients, diluents and/or carriers.
15. The compound according to claim 1 which is:
N 3 -Cyclopropyl-N 4 ′-(2,2-dimethylpropyl)-5-fluoro-2′-(hydroxymethyl)-6-methyl-3,4′-biphenyldicarboxamide, or a pharmaceutically acceptable salt thereof.